SCARA | Spinocerebellar Ataxia Type 1, 2, 3, 6, or 7, Repeat Expansion Analysis, Varies

This test is intended for molecular confirmation of clinically suspected spinocerebellar ataxia type 1, 2, 3, 6, or 7.

NIUC | Nickel/Creatinine Ratio, Random, Urine

This test is intended for measurement of nickel concentration for biomonitoring nickel exposure.

NIUCR | Nickel/Creatinine Ratio, Random, Urine

This test is intended for preferred specimen type for biomonitoring nickel exposure.

SCAP | Spinocerebellar Ataxia Repeat Expansion Panel, Varies

This test is intended for molecular confirmation of clinically suspected spinocerebellar ataxia.

TGRP | Testosterone, Total and Free, Serum

This test is intended for alternative, second-level test for suspected increases or decreases in physiologically active testosterone, assessment of androgen status in cases with suspected or known sex hormone-binding globulin-binding abnormalities, assessment of functional circulating testosterone in early pubertal boys and older men, assessment of functional circulating testosterone in women with symptoms or signs of hyperandrogenism, but normal total testosterone levels, monitoring of testosterone therapy or antiandrogen therapy in older men and in females.

TTFB | Testosterone, Total, Bioavailable, and Free, Serum

This test is intended for second- or third-order test for evaluating testosterone status (eg, when abnormalities of sex hormone-binding globulin are present).

CSMTU | Controlled Substance Monitoring Targeted Profile, 17 Drug Classes, Mass Spectrometry, Random, Urine

This test is intended for detecting drug use involving stimulants, benzodiazepines, and opioids. This test is not intended for use in employment-related testing.

CSMHU | Controlled Substance Monitoring Hybrid Drug Profile, 20 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine

This test is intended for detecting drug use involving stimulants, barbiturate, benzodiazepines, cocaine, opioids, and tetrahydrocannabinol. This test is not intended for use in employment-related testing.

LDPU | Limited Drug Profile, 3 Drug Classes, Immunoassay, Random, Urine

This test is intended for detecting drug use involving barbiturates, cocaine, and tetrahydrocannabinol. This test is not intended for use in employment-related testing.

GDCU | Gadolinium/Creatinine Ratio, Urine

This test is intended for measurement of gadolinium concentration for assessing chronic exposure and monitoring effectiveness of dialysis using a random urine collection.

SCCA | Squamous Cell Carcinoma Antigen, Serum

This test is intended for aids in the evaluation and monitoring of squamous cell carcinoma of the head and neck, lung, and cervix. This test should not be used to screen for carcinoma or other disorders including those of the liver, lung, or skin.

CRCGP | Hereditary Gastrointestinal Cancer Panel, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of a hereditary gastrointestinal cancer or hereditary polyposis syndrome. Establishing a diagnosis of a hereditary gastrointestinal cancer syndrome or hereditary polyposis syndrome allowing for targeted cancer surveillance based on associated risks. Identifying genetic variants associated with increased risk for gastrointestinal cancer and polyposis, allowing for predictive testing and appropriate screening of at-risk family members.

COMCP | ThyroglobuliHereditary Common Cancer Panel, Varies

This test is intended for evaluation for hereditary cancer in patients with a personal or family history suggestive of a hereditary cancer syndrome. Establishing a diagnosis of a hereditary cancer syndrome allowing for targeted cancer surveillance based on associated risks. Identifying genetic variants associated with increased risk for cancer, allowing for predictive testing, and appropriate screening of at-risk family members. Therapeutic eligibility with poly adenosine diphosphate-ribose polymerase(PARP) inhibitors based on certain gene alterations (eg, BRCA1, BRCA2,) in selected tumor types.

CDHZ | Hereditary Diffuse Gastric Cancer Syndrome, CDH1, Full Gene Analysis, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of hereditary diffuse gastric cancer (HDGC) syndrome. Establishing a diagnosis of HDGC syndrome allowing for targeted cancer surveillance based on associated risks. Identifying genetic variants associated with increased risk for HDGC syndrome allowing for predictive testing of at-risk family members.

BRGYP | Hereditary Breast/Gynecologic Cancer Panel, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of a hereditary breast or gynecological cancer syndrome. Establishing a diagnosis of a hereditary breast or gynecological cancer syndrome allowing for targeted cancer surveillance based on associated risks. Identifying genetic variants associated with increased risk for breast or gynecological cancers, allowing for predictive testing and appropriate screening of at-risk family members. Therapeutic eligibility with poly adenosine diphosphate-ribose polymerase (PARP) inhibitors based on certain gene alterations (eg, BRCA1, BRCA2) in selected tumor types.

BHDZ | Birt-Hogg-Dube Syndrome, FLCN, Full Gene Analysis, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of Birt-Hogg-Dube (BHD) syndrome. Establishing a diagnosis of BHD syndrome allowing for targeted cancer surveillance based on associated risks. Identifying variants within genes known to be associated with increased risk for BHD syndrome allowing for predictive testing of at-risk family members.

BAP1Z | BAP1-Tumor Predisposition Syndrome, BAP1 Full Gene Analysis, Varies

This test is intended for evaluation of patients with a personal or family history suggestive of BAP1-tumor predisposition syndrome (BAP1-TPDS). Establishing a diagnosis of BAP1-TPDS allowing for targeted cancer surveillance based on associated risks, and identifying genetic variants associated with increased risk for BAP1-TPDS, allowing for predictive testing and appropriate screening of at-risk family members.

VHLZZ | AluVon Hippel Lindau Syndrome, VHL, Full Gene Analysis, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of Von Hippel-Lindau (VHL) syndrome. Establishing a diagnosis of a VHL allowing for targeted cancer surveillance based on associated risks, and identifying genetic variants associated with increased risk for VHL syndrome allowing for predictive testing of at-risk family members.

THYRP | Hereditary Thyroid Cancer Panel, Varies

This test is intended for evaluation of patients with a personal or family history suggestive of a hereditary thyroid cancer syndrome. Establishing a diagnosis of a hereditary thyroid cancer syndrome, allowing for targeted surveillance based on associated risks, and identifying genetic variants associated with increased risk for thyroid and other cancers, allowing for predictive testing and appropriate screening of at-risk family members.

STK1Z | Peutz-Jeghers Syndrome, STK11, Full Gene Analysis, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of Peutz-Jeghers syndrome (PJS). Establishing a diagnosis of PJS allowing for targeted cancer surveillance based on associated risks, and identifying variants within genes known to be associated with increased risk for PJS allowing for predictive testing of at-risk family members.

RETZZ | Multiple Endocrine Neoplasia Type 2 Syndrome, RET, Full Gene Analysis, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of a multiple endocrine neoplasia type 2 (MEN2) or Hirschsprung disease (HSCR). Establishing a diagnosis of MEN2 or HSCR allowing for targeted cancer surveillance based on associated risks, and identifying variants within genes known to be associated with MEN2 or HSCR allowing for predictive testing of at-risk family members.

RENCP | Hereditary Renal Cancer Panel, Varies

This test is intended for evaluation of patients with a personal or family history suggestive of a hereditary renal cancer syndrome. Establishing a diagnosis of a hereditary renal cancer syndrome allowing for targeted cancer surveillance based on associated risks, and identifying genetic variants associated with increased risk for renal and/or other cancers, allowing for predictive testing and appropriate screening of at-risk family members.

PTNZ | AluVon Hippel Lindau Syndrome, VHL, Full GePTEN Hamartoma Tumor Syndrome, PTEN Full Gene Analysis, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of PTEN hamartoma tumor syndrome (PHTS). Establishing a diagnosis of PHTS allowing for targeted cancer surveillance based on associated risks, and identifying variants within genes known to be associated with increased risk for PHTS allowing for predictive testing of at-risk family members.

PRS8P | Hereditary Prostate Cancer Panel, Varies

This test is intended for evaluation of patients with a personal or family history suggestive of a hereditary prostate cancer syndrome. Establishing a diagnosis of a hereditary prostate cancer syndrome allowing for targeted cancer surveillance based on associated risks. Identifying genetic variants associated with increased risk for prostate cancer, allowing for predictive testing and appropriate screening of at-risk family members. Therapeutic eligibility with poly adenosine diphosphate-ribose polymerase (PARP) inhibitors based on certain gene alterations (eg, BRCA1, BRCA2).

PANCP | Hereditary Pancreatic Cancer Panel, Varies

This test is intended for evaluation of patients with a personal or family history suggestive of a hereditary pancreatic cancer syndrome. Establishing a diagnosis of a hereditary pancreatic cancer syndrome, allowing for targeted cancer surveillance based on associated risks. Identifying genetic variants associated with increased risk for pancreatic cancer, allowing for predictive testing and appropriate screening of at-risk family members. Therapeutic eligibility with poly adenosine diphosphate-ribose polymerase (PARP) inhibitors based on certain gene alterations (eg, BRCA1, BRCA2).

NF1Z | Neurofibromatosis Type 1, NF1, Full Gene Analysis, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of neurofibromatosis type 1 (NF1). Establishing a diagnosis of a NF1 allowing for targeted cancer surveillance based on associated risks, and identifying genetic variants associated with increased risk for NF1 allowing for predictive testing of at-risk family members.

LYNCP | AluVon Lynch Syndrome Panel, Varies

This test is intended for establishing a diagnosis of Lynch syndrome or constitutional mismatch repair deficiency allowing for targeted cancer surveillance based on associated risks. Identification of MLH1, MSH2, MSH6, PMS2, or EPCAM variants to allow for predictive testing in family members.

LRCCZ | Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome, FH, Full Gene Analysis, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome or fumarate hydratase deficiency (FHD). Establishing a diagnosis of HLRCC or FHD allowing for targeted surveillance based on associated risks, and identifying genetic variants associated with increased risk for HLRCC syndrome allowing for predictive testing of at-risk family members.

HPGLP | Hereditary Paraganglioma/Pheochromocytoma Panel, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of a hereditary paraganglioma and pheochromocytoma (PGL/PCC) syndrome. Establishing a diagnosis of a hereditary PGL/PCC, allowing for targeted surveillance based on associated risks. Identifying genetic variants associated with increased risk for PGL/PCC, allowing for predictive testing and appropriate screening of at-risk family members.

HBOCZ | BRCA1/BRCA2 Genes, Full Gene Analysis, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of hereditary breast and ovarian cancer (HBOC) syndrome. Establishing a diagnosis of HBOC syndrome allowing for targeted cancer surveillance based on associated risks, and identifying variants within genes known to be associated with increased risk for HBOC syndrome allowing for predictive testing of at-risk family members. Therapeutic eligibility including poly adenosine diphosphate-ribose polymerase (PARP) inhibitors in select cancer types.

ENDCP | Hereditary Endocrine Cancer Panel, Varies

This test is intended for evaluation for patients with a personal or family history suggestive of a hereditary endocrine tumor syndrome. Establishing a diagnosis of a hereditary endocrine tumor syndrome, allowing for targeted surveillance based on associated risks, and Identifying genetic variants associated with increased risk for endocrine tumors, allowing for predictive testing and appropriate screening of at-risk family members.

LXCP | Hereditary Expanded Cancer Panel, Varies

This test is intended for evaluation for hereditary cancer in patients with a personal or family history suggestive of a hereditary cancer syndrome. Establishing a diagnosis of a hereditary cancer syndrome allowing for targeted cancer surveillance based on associated risks. Identifying genetic variants associated with increased risk for cancer, allowing for predictive testing and appropriate screening of at-risk family members. Therapeutic eligibility with poly adenosine diphospate-ribose polymerase (PARP) inhibitors based on certain gene alterations (eg, BRCA1, BRCA2) in selected tumor types.

WILMP | Hereditary Wilms Tumor Panel, Varies

This test is intended for evaluation of isolated and syndromic causes of Wilms tumor. Establishing a diagnosis to guide management for individuals with Wilms tumor. Identification of a familial variant to allow for predictive testing and appropriate screening of at-risk family members.

HITIG | Heparin-PF4 IgG Antibody, Serum

This test is intended for detection of IgG antibodies directed against heparin/platelet factor 4 complexes that are implicated in the pathogenesis of immune-mediated type II heparin-induced thrombocytopenia (HIT-II), spontaneous heparin platelet-factor 4 (PF4) IgG antibody, and thrombocytopenia and thrombosis occurring after severe acute respiratory syndrome coronavirus 2 adenovirus vector vaccine.